244 related articles for article (PubMed ID: 18538830)
1. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
Shergy WJ
Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
[TBL] [Abstract][Full Text] [Related]
2. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
3. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
4. Improving patient outlook in rheumatoid arthritis: experience with abatacept.
Coughlin M
J Am Acad Nurse Pract; 2008 Oct; 20(10):486-95. PubMed ID: 19128344
[TBL] [Abstract][Full Text] [Related]
5. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
[TBL] [Abstract][Full Text] [Related]
6. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
7. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
Reynolds J; Shojania K; Marra CA
Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
9. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
10. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept.
Laganà B; Vinciguerra M; D'Amelio R
Clin Drug Investig; 2009; 29(3):185-202. PubMed ID: 19243211
[TBL] [Abstract][Full Text] [Related]
11. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D
Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
[TBL] [Abstract][Full Text] [Related]
13. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.
Wells G; Li T; Tugwell P
Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444
[TBL] [Abstract][Full Text] [Related]
14. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
15. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
16. Abatacept for the treatment of rheumatoid arthritis: A review.
Kaine JL
Curr Ther Res Clin Exp; 2007 Nov; 68(6):379-99. PubMed ID: 24692770
[TBL] [Abstract][Full Text] [Related]
17. [CTLA4-Ig (abatacept)].
Harigai M
Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
[TBL] [Abstract][Full Text] [Related]
18. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
20. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept.
Cole JC; Li T; Lin P; MacLean R; Wallenstein GV
Rheumatology (Oxford); 2008 Jul; 47(7):1044-50. PubMed ID: 18487628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
